RTTNews | Jan 12, 2022 11:02AM EST

11:01 Wednesday, January 12, 2022 (RTTNews.com) - Immuron Ltd. (IMRN) shares are soaring more than 39 percent on Wednesday morning after the Australian biopharma company received funding of $4.45 million from the U.S. Department of Defense.

The funding will be aimed at testing and confirming the efficacy of a single larger dose regimen of Travelan in a controlled human infection model clinical study using the enterotoxigenic Escherichia coli strain H10407. Earlier clinical studies have demonstrated that Travelan conferred 84 to over 90 percent protective efficacy against moderate to severe diarrhea.

Currently, shares are at $3.56, up 39.06 percent from the previous close of $2.56 on a volume of 31,668,890. For the 52-week period, the shares have traded in a range of $2.32-$9.23 on average volume of 42,752.

Read the original article on RTTNews ( https://www.rttnews.com/3254631/immuron-surges-on-funding-from-us-defense-dept-to-study-efficacy-of-travelan.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved